Economic burden of disease and mortality of intracranial haemorrhage under oral FXai: a German claims data analysis
Incidence rates of ICH during oral FXai therapy were within the range of other published real-world data. Duration of hospitalisations, associated costs, and mortality were high and significantly higher for patients with ICH than for comparable patients without ICH. The high burden on the healthcare system highlights the need for preventive measures and more efficient treatment pathways for patients with ICH under oral FXai therapy.
Authors
- Stefan T. Gerner (ORCID: https://orcid.org/0000-0001-6020-8290)
- Joji B. Kuramatsu (ORCID: https://orcid.org/0000-0002-7630-7880)
- Katarina Kopke
- Michael Schultze (ORCID: https://orcid.org/0009-0002-1494-5446)
- Stefan Schwab (ORCID: https://orcid.org/0000-0002-8487-1238)
- Nils Kossack (ORCID: https://orcid.org/0000-0002-9521-3898)
- Felix Scherg
- Hagen B. Huttner
Institutions
- Universitätsklinikum Gießen und Marburg (DE)
- Universitätsklinikum Erlangen (DE)
- RoMed Kliniken (DE)
- AstraZeneca (Germany) (DE)
- Berlin Center for Epidemiology and Health Research (DE)
Publication Details
- Journal
- Neurological Research and Practice
- Published
- 2025-03-30
- DOI
- https://doi.org/10.1186/s42466-025-00366-3
- Citations
- 1
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Universitätsklinikum Erlangen